State of the Art: Ultra-Low Contrast PCI

Allen Jeremias, MD, MSc, is the Director of Interventional Cardiology Research and Associate Director of the Cardiac Catheterization Laboratory at St. Francis Hospital in Roslyn, New York. He is also a member of the Cardiovascular Research Foundation in New York City where he currently serves as the Director of the Physiology Core Laboratory. He completed his medical training at The Cleveland Clinic Foundation, Stanford University School of Medicine, and Harvard Medical School. He has been a high volume interventional cardiologist since 2006 and recognized as a Top Doctor in the New York Metro Area by Castle Connolly. Dr. Jeremias has significantly contributed to advancing the field of interventional cardiology and he is considered one of the foremost authorities in coronary physiology and intravascular imaging. He is a co-director of the annual St. Francis Intravascular Imaging and Coronary Physiology Workshop, teaching physicians around the world on “Precision Angioplasty”. Dr. Jeremias is presently engaged in a major global study that could change the path of treating clogged arteries. Known as the ILUMIEN IV trial, this major clinical study is evaluating Optical Coherence Tomography (OCT) to guide coronary stent placement. He is also the principal investigator of DEFINE PCI, an international study on assessing the improvement in blood flow after stent placement for severe coronary blockages.

Dr Sharp qualified from Edinburgh Medical School in 1998. He was appointed as a Consultant Cardiologist at the Royal Devon and Exeter Hospital in 2011, before moving to the University Hospital of Wales, in Cardiff, UK in the summer of 2019, where he is now Honorary Professor of Cardiology. He conducted his early training at the Royal Infirmary of Edinburgh, before moving to London for his senior clinical training. He completed the Milan-Imperial Interventional Cardiology Fellowship programme, having spent a year in San Raffaele and Columbus Hospitals, Milan, Italy, under the tutelage of Professor Antonio Colombo. He also spent three years training in interventional cardiology at St Mary’s Hospital and The Hammersmith Hospital (Imperial College Hospitals) in London. Prof Sharp was awarded an MD postgraduate research degree from the University of Edinburgh for his work on the hypertensive heart and leads a large research programme in Wales. He has an international reputation for leading the development of device-based treatments for hypertension (in particular that of renal denervation) and pulmonary embolism, as well as the advancement of intracoronary imaging and physiology.

Prof Javier Escaned is Head of Interventional Cardiology Section at Hospital Clinico San Carlos (Madrid, Spain). He trained as a cardiologist the United Kingdom before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. With over 30 years of experience as interventionalist, he regularly serves as live case operator and educationalist in global events. He is author of over 500 PubMed indexed scientific articles (h-index 74) on topics that include complex PCI in multivessel disease, left main and chronic total occlusions. His track record in coronary physiology includes being investigator on pivotal FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR (since 2010), and developer of new methods for the assessment of microvascular and non-obstructive coronary disease. Editorial work includes two large textbooks (“Coronary Stenosis. Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation) and editorial board positions in scientific journals. Board positions in scientific societies include EuroPCR, EAPCI, EuroCTO and the ESC Working Group of Coronary Pathophysiology and Microcirculation. Additional interest incllude music and phylosophy. He is a recipient of the ESC Silver Medal and the 2022 ESC Andreas Gruentzig Award.

Dr Justin Davies is founder and CEO of Wondr Medical, inventor of iFR, and clinical academic and consultant interventional cardiologist at the National Heart and Lung Institute, Imperial College London.